nodes	percent_of_prediction	percent_of_DWPC	metapath
Lubiprostone—CLCN2—Stimuli-sensing channels—TRPM7—amyotrophic lateral sclerosis	0.0683	0.214	CbGpPWpGaD
Lubiprostone—Faecal incontinence—Riluzole—amyotrophic lateral sclerosis	0.0468	0.0778	CcSEcCtD
Lubiprostone—CLCN2—Ion channel transport—TRPM7—amyotrophic lateral sclerosis	0.0446	0.14	CbGpPWpGaD
Lubiprostone—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.0361	0.0599	CcSEcCtD
Lubiprostone—CBR1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—amyotrophic lateral sclerosis	0.0207	0.0647	CbGpPWpGaD
Lubiprostone—CLCN2—spinal cord—amyotrophic lateral sclerosis	0.0174	0.221	CbGeAlD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.0155	0.0486	CbGpPWpGaD
Lubiprostone—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0154	0.0257	CcSEcCtD
Lubiprostone—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.0152	0.0252	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0151	0.0251	CcSEcCtD
Lubiprostone—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.0149	0.0248	CcSEcCtD
Lubiprostone—Influenza—Riluzole—amyotrophic lateral sclerosis	0.0148	0.0246	CcSEcCtD
Lubiprostone—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0142	0.0236	CcSEcCtD
Lubiprostone—CBR1—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.0138	0.0434	CbGpPWpGaD
Lubiprostone—CLCN2—cerebellum—amyotrophic lateral sclerosis	0.0138	0.175	CbGeAlD
Lubiprostone—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.0137	0.0228	CcSEcCtD
Lubiprostone—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.0135	0.0224	CcSEcCtD
Lubiprostone—CBR1—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.0132	0.0415	CbGpPWpGaD
Lubiprostone—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.0128	0.0213	CcSEcCtD
Lubiprostone—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.0117	0.0194	CcSEcCtD
Lubiprostone—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.0117	0.0194	CcSEcCtD
Lubiprostone—CLCN2—brain—amyotrophic lateral sclerosis	0.0112	0.142	CbGeAlD
Lubiprostone—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.0107	0.0178	CcSEcCtD
Lubiprostone—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0173	CcSEcCtD
Lubiprostone—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.0103	0.0172	CcSEcCtD
Lubiprostone—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.0102	0.0169	CcSEcCtD
Lubiprostone—CBR1—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.0101	0.0317	CbGpPWpGaD
Lubiprostone—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0168	CcSEcCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.01	0.0313	CbGpPWpGaD
Lubiprostone—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00993	0.0165	CcSEcCtD
Lubiprostone—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00968	0.0161	CcSEcCtD
Lubiprostone—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00958	0.0159	CcSEcCtD
Lubiprostone—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00932	0.0155	CcSEcCtD
Lubiprostone—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00926	0.0154	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.00922	0.0289	CbGpPWpGaD
Lubiprostone—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00913	0.0152	CcSEcCtD
Lubiprostone—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00908	0.0151	CcSEcCtD
Lubiprostone—Cough—Riluzole—amyotrophic lateral sclerosis	0.00901	0.015	CcSEcCtD
Lubiprostone—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00879	0.0146	CcSEcCtD
Lubiprostone—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00879	0.0146	CcSEcCtD
Lubiprostone—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00876	0.0146	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00873	0.0145	CcSEcCtD
Lubiprostone—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00869	0.0144	CcSEcCtD
Lubiprostone—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.0086	0.0143	CcSEcCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.0085	0.0266	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.0085	0.0266	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.00844	0.0264	CbGpPWpGaD
Lubiprostone—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00843	0.014	CcSEcCtD
Lubiprostone—Shock—Riluzole—amyotrophic lateral sclerosis	0.00829	0.0138	CcSEcCtD
Lubiprostone—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00827	0.0137	CcSEcCtD
Lubiprostone—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00823	0.0137	CcSEcCtD
Lubiprostone—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00819	0.0136	CcSEcCtD
Lubiprostone—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00815	0.0135	CcSEcCtD
Lubiprostone—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00804	0.0134	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00784	0.0246	CbGpPWpGaD
Lubiprostone—CBR1—medulla oblongata—amyotrophic lateral sclerosis	0.00783	0.0993	CbGeAlD
Lubiprostone—CBR1—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00781	0.0245	CbGpPWpGaD
Lubiprostone—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00768	0.0128	CcSEcCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.00758	0.0237	CbGpPWpGaD
Lubiprostone—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00752	0.0125	CcSEcCtD
Lubiprostone—CBR1—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.00746	0.0234	CbGpPWpGaD
Lubiprostone—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00742	0.0123	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.00737	0.0231	CbGpPWpGaD
Lubiprostone—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00733	0.0122	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00728	0.0121	CcSEcCtD
Lubiprostone—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00727	0.0121	CcSEcCtD
Lubiprostone—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00721	0.012	CcSEcCtD
Lubiprostone—Pain—Riluzole—amyotrophic lateral sclerosis	0.00721	0.012	CcSEcCtD
Lubiprostone—CBR1—spinal cord—amyotrophic lateral sclerosis	0.00698	0.0885	CbGeAlD
Lubiprostone—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00695	0.0115	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00689	0.0115	CcSEcCtD
Lubiprostone—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00666	0.0111	CcSEcCtD
Lubiprostone—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00621	0.0103	CcSEcCtD
Lubiprostone—CBR1—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00611	0.0191	CbGpPWpGaD
Lubiprostone—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00605	0.01	CcSEcCtD
Lubiprostone—CBR1—nervous system—amyotrophic lateral sclerosis	0.00588	0.0746	CbGeAlD
Lubiprostone—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00577	0.00958	CcSEcCtD
Lubiprostone—CBR1—central nervous system—amyotrophic lateral sclerosis	0.00566	0.0718	CbGeAlD
Lubiprostone—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00557	0.00926	CcSEcCtD
Lubiprostone—CBR1—cerebellum—amyotrophic lateral sclerosis	0.00554	0.0702	CbGeAlD
Lubiprostone—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00536	0.00891	CcSEcCtD
Lubiprostone—Rash—Riluzole—amyotrophic lateral sclerosis	0.00532	0.00883	CcSEcCtD
Lubiprostone—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00531	0.00882	CcSEcCtD
Lubiprostone—Headache—Riluzole—amyotrophic lateral sclerosis	0.00528	0.00877	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.00505	0.0158	CbGpPWpGaD
Lubiprostone—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00501	0.00832	CcSEcCtD
Lubiprostone—CBR1—brain—amyotrophic lateral sclerosis	0.0045	0.057	CbGeAlD
Lubiprostone—CBR1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00411	0.0129	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00411	0.0129	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.00383	0.012	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00376	0.0118	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00349	0.0109	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00328	0.0103	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—DAO—amyotrophic lateral sclerosis	0.00297	0.0093	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00225	0.00705	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GSR—amyotrophic lateral sclerosis	0.00208	0.00651	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.00189	0.00593	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CHAT—amyotrophic lateral sclerosis	0.00171	0.00534	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.00156	0.00488	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.00107	0.00334	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000917	0.00287	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000842	0.00264	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—APOE—amyotrophic lateral sclerosis	0.000693	0.00217	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000475	0.00149	CbGpPWpGaD
